for therapeutic drug monitoring, no reference method measures only the parent drug, mainly because of the poor absorptivity of tacrolimus in ultraviolet light. We have developed a method displaying an increased specificity towards the unchanged drug, using conventional equipment available in most clinical laboratories. After chromatographic separation of the blood extract, the tacrolimus fraction is analyzed by an automated microparticle enzyme immunoassay (MEIA) performed on the lMx analyzer (Abbott Labs.). This method is linear from 0 to 40 g/L, yields CVs from 8.5% to 18.2%, and has a detection limit of 5 g/L.
Tacrolimus concentrations obtained by HPLC-MEIA in hepatic and renal transplant patients are from 47.5% to 18.8% lower than those obtained by MEIA, according to liver function tests and metabolite accumulation, even though no significant differences were observed between the methods for drugfree blood samples supplemented with known amounts of tacrolimus. 
Results
The absolute recovery yield of the combined procedure (HPLC-MEIA) was independent of tacrolimus concentration and has been evaluated as 51% ± 6% (mean ± SD). Linear regression analyses performed between observed HPLC-MEIA values (y) and direct MEIA concentrations (x) with either supplemented blood samples ranging from 0 to 40 p.gfL (n = 51; 7 stratified data) or blood samples from kidney-transplanted patients (n = 54; 7 stratified data) and livertransplanted patients (n = 254; 14 stratified data) are ifiustrated in Fig. 1 The experimental specific assay described here is likely to be most useful for pharmacokinetic studies and as a reference method for research purposes. Even though quite time consuming (10 samples assayed in -5 h), it does not involve sophisticated or onerous equipment as described in other specific experimental methods (10) (11) (12) .
The relatively low recovery of our assay can be partly explained by the acetonitrile extraction (recovery yield: 85%), and by a loss corresponding to the injection of only 50 L from the 70 L used for the resolubilization.
Whole-blood MEIA FK 506 trough concentrations seem to correlate with the area under the time-concentration curve, the mixed lymphocyte culture test, and most likely with the toxicity of treatment as observed in our center (data to be published). However, there is still a need for developing a fast, accurate, and sensitive specific assay for TDM allowing further studies to assess the potential advantages of a specific vs a nonspecific assay to optimally balance efficacy and toxicity.
